Update on herpes virus infections of the nervous system

Current Neurology and Neuroscience Reports

Volumn 13, Issue 12, 2013, Pages

  Steiner, Israel ^a   Benninger, Felix ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

Herpes simplex encephalitis; Herpes virus infections; HSE; HSV; HSV 1; HSV 2; Nervous system

Indexed keywords

ACICLOVIR; DEXAMETHASONE; HERPES SIMPLEX VACCINE; IMMUNOGLOBULIN G ANTIBODY; INTERFERON; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; TOLL LIKE RECEPTOR 3; VIDARABINE; HERPES VACCINE;

ADJUVANT THERAPY; ARTICLE; ASEPTIC MENINGITIS; CYTOKINE RELEASE; GENITAL HERPES; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; IMMUNE EVASION; NEWBORN INFECTION; NONHUMAN; RECURRENT INFECTION; VIRAL CLEARANCE; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS REPLICATION; GENETICS; HERPESVIRIDAE INFECTIONS; HUMAN ALPHAHERPESVIRUS 1; NERVOUS SYSTEM DISEASES; NEWBORN; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; HUMANS; INFANT, NEWBORN; NERVOUS SYSTEM DISEASES; VIRUS LATENCY;

MLCS; MLOWN;

EID: 84885508544     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-013-0414-8     Document Type: Article

References (93)

1. Gilden DH, Mahalingam R, Cohrs RJ, Tyler KL. Herpesvirus infections of the nervous system. Nat Clin Pract Neurol. 2007;3:82-94.
2. Dolan A, Jamieson FE, Cunningham C. The genome sequence of herpes simplex virus type 2. J Virol. 1998;72:2010-21.
3. McGeoch DJ, Dolan A, Donald S, Brauer DHK. Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1. Nucl Acids Res. 1986;14:1727-45.
4. McGeoch DJ. The genomes of the human herpesviruses: contents, relationships, and evolution. Annu Rev Microbiol. 1989;43:235-65.
5. • Egan KP, Wu S, Wigdahl B, Jennings SR. Immunological control of herpes simplex virus infections. J Neurovirol. 2013;19:328-45. Comprehensive description of immune mechanisms involved in latency and virus control.
6. Kennedy PGE, Chaudhuri A. Herpes simplex encephalitis. J Neurol Neurosurg Psychiatry. 2002;73:237-38.
7. Steiner I. Herpes simplex virus meningoencephalitis. In: Jackson AC, editor. Viral infections of the human nervous system. Birkhäuser advances in infectious diseases. Basel: Springer; 2013. pp. 47-63.
8. Abaitua F, Zia R, Hollinshead M, O'Hare P. Polarised cell migration during cell-to-cell transmission of herpes simplex virus in human skin keratinocytes. J Virol. 2013;87:7921-32.
9. Lee JI, Sollars PJ, Baver SB, Pickard GE. A herpesvirus encoded deubiquitinase is a novel neuroinvasive determinant. PLoS Pathogens. 2009;5:e1000387.
10. Böttcher S, Maresch C, Granzow H, Klupp BG, Teifke JP, Mettenleiter TC. Mutagenesis of the active-site cysteine in the ubiquitin-specific protease contained in large tegument protein pUL36 of pseudorabies virus impairs viral replication in vitro and neuroinvasion in vivo. J Virol. 2008;82:6009-16.
11. Antinone SE, Smith GA. Retrograde axon transport of herpes simplex virus and pseudorabies virus: a live-cell comparative analysis. J Virol. 2010;84:1504-12.
12. Feierbach B, Bisher M, Goodhouse J, Enquist LW. In Vitro analysis of transneuronal spread of an alphaherpesvirus infection in peripheral nervous system neurons. J Virol. 2007;81:6846-57.
13. Granstedt AE, Brunton BW, Enquist LW. (2013) Imaging the transport dynamics of single alphaherpesvirus particles in intact peripheral nervous system explants from infected mice. mBio 4: e00358-13-e00358-13.
14. Bertke AS, Apakupakul K, Ma A, Imai Y, Gussow AM, Wang K, et al. LAT region factors mediating differential neuronal tropism of HSV-1 and HSV-2 do not act in trans. PLoS One. 2012;7:e53281.
15. Bloom DC, Kwiatkowski DL. HSV-1 latency and the roles of the LATs. In Weller (ed.) Alphaherpesviruses: molecular virology. Caister Academic Press; 2011, pp. 286-312.
16. Bertke AS, Swanson SM, Chen J, Imai Y, Kinchington PR, Margolis TP. A5-positive primary sensory neurons are nonpermissive for productive infection with herpes simplex virus 1 in vitro. J Virol. 2011;85:6669-77.
17. Knipe DM, Cliffe A. Chromatin control of herpes simplex virus lytic and latent infection. Nat Rev Micro. 2008;6:211-21.
18. Bloom DC, Giordani NV, Kwiatkowski DL. Epigenetic regulation of latent HSV-1 gene expression. Biochim Biophys Acta. 2010;1799:246-56.
19. Su Y-H, Moxley MJ, Ng AK, Lin J, Jordan R, Fraser NW, et al. Stability and circularization of herpes simplex virus type 1 genomes in quiescently infected PC12 cultures. J Gen Virol. 2002;83:2943-50.
20. Steiner I, Spivack JG, O'Boyle DR, Lavi E, Fraser NW. Latent herpes simplex virus type 1 transcription in human trigeminal ganglia. J Virol. 1988;62:3493-6.
21. Stevens JG, Wagner EK, Devi-Rao GB, Cook ML, Feldman LT. RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science. 1987;235:1056-9.
22. Trousdale MD, Steiner I, Spivack JG, Deshmane SL, Brown SM, MacLean AR, et al. In vivo and in vitro reactivation impairment of a herpes simplex virus type 1 latency-associated transcript variant in a rabbit eye model. J Virol. 1991;65:6989-93.
23. Steiner I, Spivack JG, Lirette RP, Brown SM, MacLean AR, Subak-Sharpe JH, et al. Herpes simplex virus type 1 latency-associated transcripts are evidently not essential for latent infection. EMBO J. 1989;8:505-11.
24. Carpenter D, Hsiang C, Brown DJ, Jin L, Osorio N, BenMohamed L, et al. Stable cell lines expressing high levels of the herpes simplex virus type 1 LAT are refractory to caspase 3 activation and DNA laddering following cold shock induced apoptosis. Virology. 2007;369:12-8.
25. Branco FJ, Fraser NW. Herpes simplex virus type 1 latency-associated transcript expression protects trigeminal ganglion neurons from apoptosis. J Virol. 2005;79:9019-25.
26. Perng G-C, Jones C. Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle. In Solbrig (ed.) Interdisciplinary perspectives on infectious diseases. Hindawi Publishing Corporation;2010, pp. 1-18.
27. Jurak I, Silverstein LB, Sharma M, Coen DM. Herpes simplex virus is equipped with RNA-and protein-based mechanisms to repress expression of ATRX, an effector of intrinsic immunity. J Virol. 2012;86:10093-102.
28. •• Nicoll MP, Proença JT, Efstathiou S. The molecular basis of herpes simplex virus latency. FEMS Microbiol Rev. 2012;36:684-705. Latest experimental research on the control of herpes virus latency in neurons.
29. Held K, Derfuss T. Control of HSV-1 latency in human trigeminal ganglia - current overview. J Neurovirol. 2011;17:518-27.
30. Goldenberg D, Mador N, Ball MJ, Panet A, Steiner I. The abundant latency-associated transcripts of herpes simplex virus type 1 are bound to polyribosomes in cultured neuronal cells and during latent infection in mouse trigeminal ganglia. J Virol. 1997;71:2897-904.
31. Feldman LT. Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci U S A. 2002;99:978-83.
32. Wysocka J, Herr W. The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends Biochem Sci. 2003;28:294-304.
33. Thompson RL, Preston CM, Sawtell NM. De novo synthesis of VP16 coordinates the exit from HSV latency in vivo. PLoS Pathogens. 2009;5:e1000352.
34. Huang J, Lazear HM, Friedman HM. Completely assembled virus particles detected by transmission electron microscopy in proximal and mid-axons of neurons infected with herpes simplex virus type 1, herpes simplex virus type 2 and pseudorabies virus. Virology. 2011;409:12-6.
35. Wisner TW, Sugimoto K, Howard PW, Kawaguchi Y, Johnson DC. Anterograde transport of herpes simplex virus capsids in neurons by both separate and married mechanisms. J Virol. 2011;85:5919-28.
36. Karasneh GA, Shukla D. Herpes simplex virus infects most cell types in vitro: clues to its success. Virol J. 2011;8:481.
37. Kaye S, Choudhary A. Herpes simplex keratitis. Prog Retin Eye Res. 2006;25:355-80.
38. • Steiner I. Herpes simplex virus encephalitis: new infection or reactivation? Curr Opin Neurol. 2011;24:268-74. Discussion about the etiology of herpes encephalitis and if to consider a primary injection or reactivation.
39. Solomon T, Michael B, Smith P, Sanderson F. Management of suspected viral encephalitis in adults-Association of British Neurologists and British Infection Association National Guidelines. J Infect. 2012;64:347-73.
40. Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986;314:144-9.
41. Whitley RJ. Viral encephalitis. N Engl J Med. 1990;323:242-50.
42. Kennedy PGE, Steiner I. Recent issues in herpes simplex encephalitis. J Neurovirol. 2013;19:346-50.
43. Landau Z, Miller E, Roif M. Recurrent herpes simplex encephalitis. Eur J Int Med. 2005;16:513-14.
44. Yamada S, Kameyama T, Nagaya S, Hashizume Y, Yoshida M. Relapsing herpes simplex encephalitis: pathological confirmation of viral reactivation. J Neurol Neurosurg Psychiatry. 2003;74:262-4.
45. Whitley RJ. Herpes simplex virus. In: Sheld, Whitley, and Marra (eds.) Infections of the central nervous system. Lippincott Williams & Wilkins; 2004, pp. 123-44.
46. Whitley RJ. Herpes simplex encephalitis clinical assessment. JAMA. 1982;247:317-20.
47. Baskin HJ, Hedlund G. Neuroimaging of herpesvirus infections in children. Pediatr Radiol. 2007;37:949-63.
48. Castillo M, Rumboldt Z. Herpes simplex encephalitis. In Rumboldt et al. (ed.) Brain imaging with MRI and CT: an image pattern approach. Cambridge University Press, New York 2012, pp. 41-2
49. Esiri MM. Herpes simplex encephalitis: an immunohistological study of the distribution of viral antigen within the brain. J Neurol Sci. 1982;54:209-26.
50. Tissari J, Sirén J, Meri S, Julkunen I, Matikainen S. IFN-α enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol. 2005;174:4289-94.
51. •• Okun E, Griffioen KJ, Mattson MP. Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci. 2011;34:269-81. Very comprehensive summary of Toll-like receptor functions.
52. Okun E, Griffioen KJ, Lathia JD, Tang SC. Toll-like receptors in neurodegeneration. Brain Res. 2009;59:278-92.
53. Guo Y, Audry M, Ciancanelli M, Alsina L, Azevedo J, Herman M, et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J Exp Med. 2011;208:2083-98.
54. Sancho-Shimizu V, deDiego RP, Lorenzo L, Halwani R, et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J Clin Invest. 2011;121:4889.
55. Herman M, Ciancanelli M, Ou YH, Lorenzo L, Klaudel-Dreszler M, Pauwels E, et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J Exp Med. 2012;209:1567-82.
56. Zhang S-Y, Jouanguy E, Ugolini S, Smahi A, Elain G, Romero P, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science. 2007;317:1522-7.
57. Leib DA. Herpes simplex virus encephalitis: Toll-free access to the brain. Cell Host Microbe. 2012;12:731-2.
58. Lafaille FG, Pessach IM, Zhang S-Y, Ciancanelli MJ, Herman M, Abhyankar A, et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature. 2012;491:769-73.
59. Zhang S-Y, Herman M, Ciancanelli MJ, de Diego RP, Sancho-Shimizu V, Abel L, et al. TLR3 immunity to infection in mice and humans. Curr Opin Immunol. 2013;25:19-33.
60. Perales-Linares R, Navas-Martin S. Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology. 2013;140:153-67.
61. Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol. 2006;6:940-52.
62. Smyth MJ, Trapani JA. Granzymes: exogenous porteinases that induce target cell apoptosis. Immunol Today. 1995;16:202-6.
63. Barber GN. Host defense, viruses and apoptosis. Cell Death Differ. 2001;8:113-26.
64. Joly E, Mucke L, Oldstone M. Viral persistence in neurons explained by lack of major histocompatibility class I expression. Science. 1991;253:1283-5.
65. Oldstone MB. Molecular anatomy of viral persistence. J Virol. 1991;65:6381.
66. Knickelbein JE, Hendricks RL, Charukamnoetkanok P. Management of herpes simplex virus stromal keratitis: an evidence-based review. Survey Ophthalmol. 2009;54:226-34.
67. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, et al. The role of virus-specific Cd8+ cells in liver damage and viral control during persistent hepatitis b virus infection. J Exp Med. 2000;191:1269-80.
68. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. Hepatology. 1999;30:595-601.
69. Steiner I, Budka H, Chaudhuri A, Koskiniemi M, Sainio K, Salonen O, et al. Viral meningoencephalitis: a review of diagnostic methods and guidelines for management. Eur J Neurol. 2010;17:999-e57.
70. Cinque P, Cleator GM, Weber T, Monteyne P, Sindic CJ, van Loon AM. The role of laboratory investigation in the diagnosis and management of patients with suspected herpes simplex encephalitis: a consensus report. The EU Concerted Action on Virus Meningitis and Encephalitis. J Neurol Neurosurg Psychiatry. 1996;61:339-45.
71. Benninger F, Steiner I. Steroids in bacterial meningitis: yes. J Neural Transm. 2013;120:339-42.
72. Quagliarello V, Scheld WM. Infectious disease: do steroids benefit patients with bacterial meningitis? Nat Rev Neurol. 2010;:529-30.
73. Jacobs DH. Herpes simplex virus encephalitis following corticosteroids and cranial irradiation. Neurology. 1999;52:1106.
74. Thompson KA, Blessing WW, Wesselingh SL. Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal Herpes encephalitis. J Neurovirol. 2000;6:25-32.
75. Meyding-Lamadé UK, Oberlinner C, Rau PR. Experimental herpes simplex virus encephalitis: a combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities. J Neurovirol. 2003;9:118-25.
76. Almalki DM, Al-Suwaidan FB. Steroid pulse therapy in herpes simplex encephalitis. Neurosciences (Riyadh). 2013;18:276-7.
77. Kamei S. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry. 2005;76:1544-9.
78. Lizarraga KJ, Alexandre LC, Ramos-Estebanez C, Merenda A. Are steroids a beneficial adjunctive therapy in the immunosuppressed patient with herpes simplex virus encephalitis? Case Rep Neurol. 2013;5:52-5.
79. • Martinez-Torres F, Menon S, Pritsch M, Victor N, Jenetzky E, Jensen K, et al. German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. BMC Neurol. 2008;8:40. Initial description of the GACHE trial; still awaiting results.
80. VanLandingham KE, Marsteller HB. Relapse of herpes simplex encephalitis after conventional acyclovir therapy. JAMA. 1988;259:1051-3.
81. Ito Y, Kimura H, Yabuta Y, Ando Y. Exacerbation of herpes simplex encephalitis after successful treatment with acyclovir. Clin Infect Dis. 2000;30:185-7.
82. Kimura H, Aso K, Kuzushima K, Hanada N. Relapse of herpes simplex encephalitis in children. Pediatrics. 1992;89:891-4.
83. Sköldenberg B, Aurelius E, Hjalmarsson A, Sabri F. Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J Neurol. 2006;253:163-70.
84. Barthez-Carpentier MA, Rozenberg F. Relapse of herpes simplex encephalitis. J Child Neurol. 1995;10:363-8.
85. Gable MS, Sheriff H, Dalmau J. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California. Clin Infect Dis. 2012;54:899-904.
86. Armangue T, Titulaer MJ, Málaga I, Bataller L. Pediatric anti-N-methyl-D-aspartate receptor encephalitis - clinical analysis and novel findings in a series of 20 patients. J Pediatr. 2013;162:850-6.
87. Berger JR, Houff S. Neurological complications of herpes simplex virus type 2 infection. Arch Neurol. 2008;65:596-600.
88. Logan SAE, MacMahon E. Viral meningitis. BMJ. 2008;336:36-40.
89. Thompson C, Whitley R. Neonatal herpes simplex virus infections: where are we now? Adv Exp Med Biol. 2011;697:221-30.
90. James SH, Kimberlin DW, Whitley RJ. Antiviral therapy for herpesvirus central nervous system infections: Neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection. Antiviral Res. 2009;83:207-13.
91. Whitley R. Neonatal herpes simplex virus infection. Curr Opin Infect Dis. 2004;17:243-6.
92. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347:1652-61.
93. Belshe R.B.Leone P.A.Bernstein D.I. Efficacy results of a trial of a herpes simplex vaccine N Engl J Med 2012 366 34-43 22216840 10.1056/ NEJMoa1103151 1:CAS:528:DC%2BC38XhtVKitL4%3D